Novo Nordisk A/S (NYSE:NVO) Shares Sold by Valeo Financial Advisors LLC

Valeo Financial Advisors LLC lowered its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 14.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 27,715 shares of the company's stock after selling 4,519 shares during the period. Valeo Financial Advisors LLC's holdings in Novo Nordisk A/S were worth $1,925,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of NVO. Stratos Investment Management LLC increased its stake in shares of Novo Nordisk A/S by 63.2% during the 1st quarter. Stratos Investment Management LLC now owns 84,046 shares of the company's stock worth $5,836,000 after purchasing an additional 32,559 shares during the last quarter. May Hill Capital LLC lifted its holdings in shares of Novo Nordisk A/S by 79.7% during the 1st quarter. May Hill Capital LLC now owns 8,753 shares of the company's stock worth $608,000 after acquiring an additional 3,883 shares during the period. NTV Asset Management LLC lifted its stake in Novo Nordisk A/S by 8.1% in the 1st quarter. NTV Asset Management LLC now owns 9,954 shares of the company's stock valued at $691,000 after purchasing an additional 748 shares during the last quarter. Hourglass Capital LLC lifted its stake in Novo Nordisk A/S by 9.9% in the 1st quarter. Hourglass Capital LLC now owns 20,820 shares of the company's stock valued at $1,446,000 after purchasing an additional 1,870 shares during the last quarter. Finally, Walter Public Investments Inc. raised its stake in shares of Novo Nordisk A/S by 5.5% during the first quarter. Walter Public Investments Inc. now owns 209,977 shares of the company's stock valued at $14,581,000 after acquiring an additional 10,920 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Finally, Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Price Performance

NVO traded up $1.70 during trading hours on Thursday, hitting $71.39. The company's stock had a trading volume of 3,112,584 shares, compared to its average volume of 7,276,210. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. The business's 50-day moving average price is $70.25 and its 200-day moving average price is $75.33. The stock has a market cap of $318.74 billion, a price-to-earnings ratio of 21.09, a P/E/G ratio of 1.36 and a beta of 0.64. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $143.49.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The business had revenue of $11.87 billion during the quarter. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.